TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Interaction Between Paroxetine and Telaprevir

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is at least 18 and not older than 65 years at screening.~* Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.~* Subject has a chronic HCV infection with genotype 1.~* Subject is eligible for telaprevir containing HCV treatment.~* Subject is on a stable dose of 20 mg paroxetine once daily for at least 4 weeks.~Exclusion Criteria:~* Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.~* Pregnant female (as confirmed by a human chorionic gonadotropin (HCG) test performed less than 6 weeks before Day -1) or breast-feeding female. Female subjects of childbearing potential without adequate contraception, e.g. hysterectomy, bilateral tubal ligation, (non-hormonal) intrauterine device, total abstinence, double barrier methods, or two years post-menopausal. They must agree to take precautions in order to prevent a pregnancy throughout.~* Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.~* Inability to understand the nature and extent of the trial and the procedures required.~* Participation in a drug trial within 60 days prior to the first dose of telaprevir.~* Use of relevant concomitant medication, as assessed by a hospital pharmacist (member of the study team).~* Hemoglobin \< 12 g/dL (females) or \< 13 g/dL (males) (7.4 respectively 8.0 mM).~* Poor- or ultrarapid metabolizer CYP2D6 (based on genetic testing)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- paroxetine alone (Type: ACTIVE_COMPARATOR): paroxetine 20 mg tablet once daily oral
- paroxetine + telaprevir (Type: EXPERIMENTAL): paroxetine 20 mg tablet once daily + telaprevir 1125 mg (3 tablets 375mg) twice daily oral

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: REPEAT Study - Resistance to ErythroPoietin Effectiveness Algorithm Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* written informed consent~* Adult patients \> 18 years old with current Epoetin Alpha dose \>250 units/kg/wk~* Hemoglobin \>90g/L or \<130g/L~* Patients whom a temporary fall in Hb of up to 10g/L is deemed safe~* Patients not expected to have a change in the type of Epo or route of Epo therapy for the duration of the Study period~Exclusion Criteria:~* Known iron deficiency (% saturation \<20 or ferritin \<100)~* Vit B12 or folate deficiency (levels below normal limit for centre lab)~* Known malignancy (solid organ, leukemia or multiple myeloma)~* Jehovah's witness patients/those who refuse transfusion~* Expected to die in the next 6 months~* On dialysis less than 3 months~* Temporary (not tunneled) dialysis access catheter~* Pure red cell aplasia~* High likelihood of early withdrawal or interruption of the study (eg. severe or unstable coronary artery disease, stroke, severe liver disease within the 12 weeks before screening)~* Planned major elective surgery during the study period~* Pregnancy or breast-feeding~* Women of child-bearing potential without effective contraception (abstinence, oral contraceptives, diaphragm, IUD)~* Administration of another investigational drug within 4 weeks before screening or planned during study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: NO_INTERVENTION): Epo dose to remain constant throughout study
- Dosage Decrease Arm (Type: ACTIVE_COMPARATOR): Arm 2 is to have an decrease of erythropoietin at regular intervals.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Establishing the Genetic Profile of Multiple Hereditary Exostoses (HME) in Families of BC

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with HME

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: SNPeCPR In Cardiac Arrest REsuscitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with out of hospital cardiac arrest~* Age\> 18 years and \<75 years~* Initial Rhythm: Ventricular fibrillation or ventricular tachycardia or pulseless electrical activity~Exclusion Criteria:~* out of hospital cardiac arrest of non-cardiac origin:~  * trauma~ * anoxic, including drowning~ * hemorrhage,~ * overdose (drugs),~ * drug,~ * electric~* Do Not Resuscitate Order,~* obvious signs of clinical death (decomposition, cadaveric rigidity, decapitation)~* recent sternotomy (\<6 months or recent scar)~* Contraindications related to sodium nitroprusside~  * Women of childbearing age (between 18 and 55 years)~ * Other contra-indications will usually not known during resuscitation in case of presence of a relative rescue team must be searched: Hypothyroidism, Sulfuryl transferase deficiency (rhodanese Lang) currently recognized in patients with Leber optic atrophy, tobacco amblyopia or severe hepatic impairment.~* Obesity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Intervention arm (Type: EXPERIMENTAL): Pharmaco- mechanical optimization
- Mechanical optimization only (Type: ACTIVE_COMPARATOR): Mechanical optimization only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cardiometabolic Disease and Pulmonary Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 30-80 years~* History of obesity and current BMI ≥ 25 kg/ m2 for study volunteers or BMI ≥ 25 kg/ m2 for those with clinically indicated CPET or known HFpEF~* History of Dyspnea (Grade 1 or more)~* Able to provide informed consent and willing to comply with study~Exclusion Criteria:~* History of diabetes mellitus~* History of primary pulmonary arterial hypertension~* History of moderate to severe COPD~* History of severe Obstructive Sleep apnea~* History of renal disease (eGFR\< 45 mL/min/1.732)~* History of severe liver disease~* History of cardiovascular disease (recent heart attack or stroke) except known HFpEF~* History of blood clot in lung~* History of Splenectomy~* History of Active Cancer~* Platelets count of \< 75,000~* International normalized ration (INR) of \> 1.5~* History of recent anemia (HB \< 9g/dL)~* Current use of Metformin~* Prior LVEF \< 50% on echocardiogram~* Indication of severe valvular disease on echo~* Pregnant or planning to become pregnant in next 4 months~* History of HIV infection

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: ACTIVE_COMPARATOR): Metformin: 500mg twice daily for 1 week, followed by 1g twice daily for a total of 3 months.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo: 500 mgh twice daily for 1 week, followed by 1g twice daily for a total of 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Preimplantation Genetic Diagnosis (PGD) by Array Comparative Genome Hybridization (CGH) and Blastocyst Biopsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Couples with women 30-42 years of age~* Follicle Stimulating Hormone (FSH) level \<11IU/L on day 3 of cycle.~Exclusion Criteria:~* TESA and TESE patients~* Couples' carriers of chromosomal or genetic diseases~* Couples that produce less than eight antral follicles on day 2-4 of cycle~* Patients will be excluded if they produce no blastocysts by day 5

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- Test (Type: ACTIVE_COMPARATOR): The test group will consist of patients undergoing blastocyst biopsy followed by vitrification (embryo freezing), and in which the biopsied cells will be analyzed with a comprehensive chromosome analysis technique (array Comparative Genome hybridization or aCGH) and only one chromosomally normal embryo will be replaced in a thawed cycle.
- control (Type: NO_INTERVENTION): The control group will consist of patients in which one embryo will be replaced on day 5 based on morphological and developmental characteristics, and the other embryos reaching blastocyst stage will be vitrified. If patient does not become pregnant, successive embryo transfers of frozen embryos will be performed, but not as part of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Potential Allergenicity of New Wheat Varieties

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 1 year to 21 years of any sex and any race~* Physician-diagnosed food allergy to wheat with convincing clinical history of food allergy to wheat AND a skin prick test positive to wheat (diameter of wheal 3 mm or greater than negative control) or a detectable serum food-specific IgE level (ImmunoCAP \> 0.35 kUA/L) to wheat within the previous 12 months or at the time of entry into the study~* If no history of clinical reactivity to wheat, then a positive skin prick test to wheat (diameter of wheal 3 mm or greater than negative control) OR a detectable serum food-specific IgE level to wheat within the previous 12 months or at the time of entry into the study~* Patients who meet any of the following criteria are eligible for enrollment as study participants if they meet all other criteria, but will not undergo a DBPCFC:~  * Recent (within one year) failed open OFC~ * Positive DBPCFC to wheat at CHCO~ * Recent (within one year) exposure to wheat resulting in immediate IgE-mediated allergic symptoms (within 2 hours of ingestion; symptoms such as urticaria, angioedema, congestion, rhinorrhea, wheezing, respiratory compromise, hypoxia, hypotension)~* Written informed consent from parent/guardian and assent (when age appropriate).~* Willingness to submit specimen for laboratory serum IgE testing~* Willingness to submit lab specimen for ELISA testing~Exclusion Criteria:~* Inability to discontinue antihistamines for skin prick testing and OFCs~* FEV1 value \<80% predicted OR any clinical features of moderate or severe persistent asthma, as defined by the 2007 NHLBI guidelines table for classifying asthma, at the time of entry into the study~* Use of \>500 μg/day fluticasone or equivalent~* Asthma requiring either:~  * 1 hospitalization in the past year for asthma, or~ * 1 ER visit in the past 6 months for asthma~* Use of steroid medications (IV, IM or oral) for asthma in the following manners:~  * history of daily oral steroid dosing for \>1 month during the past year, or~ * steroid course/burst in the past 3 months (except for steroid dosing used in the treatment of an allergic reaction during the DBPCFC), or~ * 2 steroid courses/bursts in the past year.~* History of intubation due to allergies or asthma~* Diagnosis of active eosinophilic gastrointestinal disease in the past year~* Severe atopic dermatitis, as assessed by a Three-Item Severity Score of 6 or greater

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 21 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged above 18 years with histologically or cytologically confirmed NSCLC and contrast-enhanced CT scan or Gadolinium-enhanced MRI confirmed brain metastases who have a performance status of 0 to 2~* No previous radiotherapy, surgery or chemotherapy for brain metastases~* Patients should not have any unstable systemic disease~Exclusion Criteria:~* Serious abnormal laboratory values~* Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the Investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol~* Clinically significant cardiovascular event (e.g. myocardial infarction, superior vena cava syndrome (SVC), New York Heart Association (NYHA) classification of heart disease \>2 within 3 months before entry; or presence of cardiac disease that, in the~* Previous randomization of treatment in the present study and/ or current participation in another clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ZACTIMA TM (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Patient Satisfaction During Treatment With Dupilumab in Severe and Recurrent Nasosinusal Polyposis Despite Appropriate Medical and Surgical Treatment.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Women and men over 18 years old~2. Suffering from severe and recurrent Chronic Rhinosinusitis with Nasal Polyps despite having benefited from the appropriate medical and surgical treatment.~3. CRSwNP diagnosis established on the basis of clinical presentation and patient interrogation by their referent ENT surgeon.~4. Patient treated with Dupilumab in the indication depicted in bullet point 2.~5. Patient having voiced their non-opposition to this research, having received clear and appropriate information.~6. Patient affiliated to the French Social Security.~Exclusion Criteria:~1. Patient having undergone endoscopic nasal surgery during their Dupilumab treatment.~2. Patient presenting exclusion criteria for Dupilumab treatment.~3. Patient suffering from immune deficit.~4. Patient suffering from vascularitis with nasal expression.~5. Patient whose autonomy has been reduced by a legal authority.~6. Patient unable to express their agreement to participate in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients suffering from severe recurrent CRSwNP and treated with Dupilumab (Type: None): Patients suffering from severe recurrent CRSwNP despite having benefited from the appropriate medical and surgical treatment and treated with Dupilumab for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acetaminophen vs Indomethacin in Treating hsPDA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age at birth 22 weeks to 31 6/7 weeks.~* Birth weight ≤ 1500 grams~* Day of life ≤ 21 days~* ECHO findings:~Left-to-right ductal flow AND 2 of the following 3:~* Ductal size \> 1.5mm at smallest diameter~* Reversal of flow in descending aorta~* Left atrial size to aortic root ratio \>1.5~* Platelet count \> 50,000~Exclusion Criteria:~* Ductal dependent congenital heart disease~* Major congenital anomaly~* Life-threatening infection~* Urine output \< 1cc/kg/hr in prior 8 hours~* Serum creatinine \> 1.8 mg/dL~* Hyperbilirubinemia requiring exchange transfusion~* Active NEC Stage 2 or 3 using Bell's staging criteria~* Active intestinal perforation~* Liver dysfunction \[2x upper limit of normal for aspartate aminotransferase(AST) and/or alanine aminotransferase (ALT)\]~* Active GI bleeding~* Concurrent hydrocortisone use~* Known IVH Grade 3 or 4

- Gender: ALL
- Minimum Age: 22 Weeks
- Maximum Age: 32 Weeks
- Healthy Volunteers: f

Study Arms:
- Indomethacin (Type: ACTIVE_COMPARATOR): Indomethacin as drug to treat PDA.
- Acetaminophen (Type: EXPERIMENTAL): Acetaminophen as drug to treat PDA.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Fibrolamellar hepatocellular carcinoma histopathologically proven~* Inoperable/advanced (Tumor recurrence inoperable or metastatic with no surgical indication).~* Available Tumor tissue for analysis(biopsy or surgical specimen)~* Performance status WHO ≤ 2.~* Adequate organ function :~  * Hematology (absolute neutrophil count equal or superior to 1,5 x 10\*9/l , platelet equal or superior to 100 x 10\*9/l),~ * clearance of creatinine \> 60 ml/min),~ * AST/ALT ≤ 5 N, PAL ≤ 5 N, total bilirubin ≤ 2N.~Exclusion Criteria:~* Hypersensitivity to sunitinib.~* Contraindication to sunitinib, including uncontrolled hypertension, medical history of cerebrovascular accident, unstable cardiac pathology despite optimal medical therapy (myocardial infarction within the 6 months prior to study drug administration, severe/unstable angina ), active hemorrhagic syndrome or concomitant treatment with anticoagulants.~* Any severe acute or chronic co-morbid that may compromise to comply with study participation : uncontrolled infection, symptomatic congestive heart failure, liver disturbance, chronic renal failure, active gastro-duodenal ulcer (nonexhaustive list)~* Known brain metastases.~* Diagnosis of any second malignancy within the last 3 years, except for basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri~* Current treatment on another clinical trial.~* Prior treatment with an investigational agent within 4 weeks~* Patient on i.v bisphosphonate therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patient treated (Type: EXPERIMENTAL): patient who receive sunitinib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with all types of non-valvular AF (includes paroxysmal, persistent and permanent AF)~2. Candidate for anticoagulation therapy~3. No contra-indication for LGE-MRI~4. Patients age 18 and older~5. Patients who are able to provide informed consent to participate in the study~Exclusion Criteria:~1. Patients who have already undergone an atrial fibrillation ablation procedure.~2. Patients with active contra-indications to any anticoagulant agent.~3. Other major bleeding disorders or risk factors that would place the patient at risk of bleeding.~4. Recent surgery (within 30 days).~5. Renal insufficiency, severe kidney disorders/diseases, GFR \< 30mg/dL (Gadolinium contraindication).~6. Advanced liver disease.~7. Any health related Gadolinium/MRI contraindications: Pacemaker devices, etc.~8. Pregnant, planning to be become pregnant or nursing women~9. Individuals who are unable to provide informed consent~10. Contraindicated for Pradaxa® .~11. Patients the Investigators feel are inappropriate for the study~12. Patients who cannot give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dabigatran (Type: EXPERIMENTAL): Patients with Atrial fibrillation taking Dabigatran etexilate as the anti-coagulant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues